Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2019 09:09 ET | Source: Tyme Technologies, Inc.

TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (Racemetyrosine) Shown to Have Anti-Tumor Response in Preclinical...
May 29, 2019 07:30 ET | Source: Tyme Technologies, Inc.

TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (racemetyrosine) Shown to Have Anti-Tumor Response in Preclinical...
May 28, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019

NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
May 24, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019

NEW YORK, May 24, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company...
May 23, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas

New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneSM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy...
May 20, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers

NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that it...
May 09, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th

NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
May 02, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019

NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
May 01, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
April 15, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces USAN Approval of Generic Name “Racemetyrosine” for SM-88

NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that...